DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers
DECAMP 1 PLUS aims to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules (8-25 mm). Molecular biomarkers for lung cancer diagnosis measured in minimally invasive and non-invasive biospecimens may be able to distinguish between malignant or benign indeterminate pulmonary nodules in high-risk smokers. Ultimately, this study aims to validate molecular as well as clinical and imaging biomarkers of lung cancer in individuals with indeterminate lung nodules.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Apr 1, 2026 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Boston University
- Interventions being studied
- Other: Institutional standard of care; Other: Biosamples of airway and blood
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Radiologic diagnosis of solid indeterminate pulmonary nodule (0.8 to 2.5 cm) identified in the past 3 months OR semi-solid (mixed density) nodule with solid component of at least 0.6 cm identified in the past 12 months; must be of appropriate size at enrollment.
- CT scan completed within 3 months prior to enrollment
- Able to tolerate all biospecimen collection as required by protocol
- Able to comply with standard of care follow up visits including clinical exams, diagnostic work-ups, and imaging for approximately three years from enrollment
- Able to complete the Patient Lung History questionnaire with study staff Arm 1 - Screening
- Age 55-77 years old
- Current and former smokers with 30 pack-years or more(and quit less than 15 years ago) Arm 2 - Incidental
- Age \> 45 years old
- Current and former smokers with 10 pack-years or more(and quit less than 15 years ago)
- History or previous diagnosis of primary lung cancer, metastatic lung cancer, or any other non-lung cancer within 5 years (not including non-melanoma skin cancer)
- Symptoms of lung cancer (unexplained weight loss 10 lbs or more in 3 months, recent hemoptysis)
- Diagnosis of pure ground glass opacities for the target lesion on chest CT within the last 12 months (i.e., mixed features on the target lesion and pure ground glass opacity on non-target lesions are acceptable as mentioned above)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Alabama, BirminghamBirmingham, Alabama
- University of California Los AngelesLos Angeles, California
- VA Greater LA Healthcare SystemLos Angeles, California
- Naval Medical Center San DiegoSan Diego, California
- University of IowaIowa City, Iowa
- Walter Reed Army Medical CenterBethesda, Maryland
- VA Boston Healthcare SystemBoston, Massachusetts
- University of MichiganAnn Arbor, Michigan
- Mayo ClinicRochester, Minnesota
- Cleveland ClinicCleveland, Ohio
- American College of Radiology [Administrative Site]Philadelphia, Pennsylvania
- University of Pennsylvania School of MedicinePhiladelphia, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 1, 2026. Always confirm current availability with the study team.